Replies to post #197990 on Enzolytics Inc (ENZC)

[Mutat]

I’m not sure where Charles stands with the company at this time. If he resigned then its over but if he is still involved him and Joseph may have the shares to call a shareholder meeting if thats even possible. Harry is power hungry and will cause the shareholders to lose their money.

[docsetc]

Possibly Not. It does not necessarily lead to a drawn-out lawsuit. If they have what they claim to, a Judge may dismiss any action brought by Harry, right out of hand, not even make it to a jury process, AND, if the CCC clan can get preferred share voting control, Harry can only whimper and leave.

It's not as dark as it seems.

[I-Glow]

There isn't a Clone 3 patent - the insiders control the vote - retail shareholders have to sit and watch their investment disappear.

Do you guys ever do any research?

"Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)

InventorJoseph P. Cotropia
Current Assignee BIO CLONETICS BIOCLONETICS IMMUNOTHERAPEUTICS Inc

Application US07/633,964 events
1990-12-26
Application filed by Bioclonetics Inc
1990-12-26
Priority to US07/633,964
1995-10-17
Publication of US5459060A
1995-10-17
Application granted
Anticipated expiration 2012-10-17
Status. Expired - Lifetime"

"Abstract
Disclosed is a human monoclonal antibody produced by the hybridoma designated Clone 3 and having A.T.C.C. Accession No. CRL 10198."

The Clone 3 patent didn't have any commercial value.

Then we have:

"A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates
J Cotropia et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul.

Abstract
A potential component that may be useful for passive immunotherapy for HIV-1 is human monoclonal antibodies (HumAbs) possessing potent anti-HIV-1 activity that is directed against conserved regions of the envelope glycoprotein. Such antibodies would, in principle, have the ability to neutralize diverse isolates of HIV-1...

Therefore, clone 3 reactivity defines a conserved neutralizable site on the HIV-1 transmembrane glycoprotein. Clone 3 and the conserved immunogenic epitope on gp41 could be useful in passive and active immunotherapy for the acquired immunodeficiency syndrome (AIDS)."

Clone 3 has been pumped since at least 1990.

ENZC has nothing of value.

IG